Tin tức & Cập nhật

Cancer history does not factor in COVID-19, related outcomes among older women

A history of cancer in older women appears to have no negative impact on the risks of COVID-19 and its outcomes, as reported in a study.

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

The combination of sintilimab plus axitinib demonstrates encouraging antitumour activity in patients with fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) while having a manageable safety profile, according to a phase II study conducted in China.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

New drug applications approved by US FDA as of 1-15 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Radiotherapy plus sacituzumab govitecan feasible in metastatic breast cancer

Concurrent administration of sacituzumab govitecan and radiotherapy is well tolerated and does not lead to increased toxicity in patients with metastatic breast cancer, a study has shown.

Peg-filgrastim reduces neutropenia in children with solid tumours

The incidence of febrile neutropenia (FN) is significantly lesser in children with solid tumours receiving pegylated filgrastim as primary prophylaxis following chemotherapy than in those assigned to filgrastim alone, reports a study. Moreover, no adverse events attributed to the study drug have been observed.

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

The growing range of treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) has made first-line decisions more complex and more critical. Patients are increasingly more aware of new and different treatment options and are seeking therapies that align with their personal values. As survival outcomes continue to improve, shared decision-making (SDM) plays a vital role in individualising care by integrating clinical evidence with what matters most to each individual. This article explores how SDM can support patient-centred care, drawing on insights from Professor James Yang and patient advocate Mark Brooke.

Vorasidenib prevents seizures in mIDH1/2 gliomas

Patients with grade 2 isocitrate dehydrogenase 1 or 2 mutant (mIDH1/2) gliomas receiving vorasidenib experience fewer seizure activities than those on placebo, as shown by the results of the INDIGO study.